New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Scribe Therapeutics Inc.

SCTX

Healthcare Biotechnology

Scribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.

12.07 1.15 −8.70%

After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.

Market cap
$250.4M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
—
Payout ratio
—

Where the cash went Q3 FY2026, quarter to Sep 30, 2026

Free cash flow was −$11.3M: capital expenditures were more than operating cash flow. Cash rose by $136.5M. What is a cash flow statement?

Free cash flow
−$11.3M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
+$136.5M over the period
Where the cash went, in millions of dollars
Operating cash flow−11.3
Capital expenditures0.0
Free cash flow−11.3
From investments, net+5.2
Shares issued, net+140.5
Other+2.0
Change in cash136.5

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Net Income

+2 more quarters

11.86 — — (9.86)
Operating Cash Flow
— — — (11.25)
Investing cash flow
— — — 5.18
Financing cash flow
— — — 142.53
Ending Cash
— — — 136.46

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026